Immunotherapy with checkpoint inhibitors prolong cancer survival, particularly in melanoma and lung tumors. They modify the immune system but may trigger immune-related adverse events (IrAEs), including death. We reviewed PubMed for IrAEs from 2005-2017. We found that dermatologic, endocrine and gastrointestinal systems most affected. For single drugs, ipilimumab, nivolumab and pembrolizumab account for the majority. In two-drug combinations, Pembrolizumab and Nivolumab, Nivolumab and Ipilimumab and Pembrolizumab and Ipilimumab account for 58% of adverse events.

Learning Objective: Learn about the immune-related adverse events associated with immunotherapy with checkpoint inhibitors, common organ systems involved and the drugs or drug combinations associated with them.

Authors:

Paul Fontelo (Presenter)
Nantional Library of Medicine

Fang Liu, Nantional Library of Medicine

Presentation Materials:

• Abstract/Manuscript - 1